Type
- Cancellation by sponsor (525)
- ARTG (454)
- Australian Public Assessment Report (AusPAR) (69)
- Prescription medicine registration (44)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (19)
- Designation or determination (9)
- Cancellation or suspension (7)
- Prescription medicine evaluation (3)
Date
- 2026 (12)
- 2025 (44)
- 2024 (86)
- 2023 (73)
- 2022 (59)
- 2021 (124)
- 2020 (107)
- 2019 (98)
- 2018 (95)
- 2017 (73)
- 2016 (12)
- 2015 (22)
- 2014 (19)
- 2013 (9)
- 2012 (8)
- 2011 (14)
- 2010 (27)
- 2009 (13)
- 2008 (5)
- 2007 (11)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (3)
- 2002 (10)
- 2001 (6)
- 2000 (20)
- 1999 (9)
- 1998 (10)
- 1997 (16)
- 1996 (6)
- 1995 (3)
- 1994 (31)
- 1993 (16)
- 1992 (5)
- 1991 (85)
Sponsor content
1151 result(s) found, displaying 111 to 120
-
Australian Public Assessment Report (AusPAR)Xeljanz (tofacitinib) was approved for the treatment of ankylosing spondylitis and for active polyarticular course juvenile idiopathic arthritis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PFIZER DAUNORUBICIN daunorubicin (as hydrochloride) 18.7 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for METHOBLASTIN methotrexate (as sodium) 10 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for METHOBLASTIN methotrexate (as sodium) 2.5 mg tablet blister pack.
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: talazoparib tosilate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SAYANA PRESS medroxyprogesterone acetate 104 mg/0.65 mL suspension for injection ampoule with attached needle.